USPTO serial 79409809
Serial No. 79409809
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 24, 2026
- Examiner
- NOVAKOVIC, MIROSLAV
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79409809?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
SHANGHAI BAO PHARMACEUTICALS CO., LTD.
CN
Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
SHANGHAI BAO PHARMACEUTICALS CO., LTD.
CN
Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
SHANGHAI BAO PHARMACEUTICALS CO., LTD.
CN
Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles Ho
Charles Ho Barron & Young PLLC5465 Legacy Drive, Suite 650Plano, TX 75024United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; pharmaceutical preparations for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; drugs for medical purposes, namely, for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; biological preparations for medical purposes, namely, for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; enzymes for medical purposes; enzyme preparations for medical purposes; adjuvants for medical purposes; injectable solutions for medical purposes, namely, for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; aqueous solutions for medical purposes, namely, for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility; biochemical drugs for the treatment of autoimmune diseases, organ transplant rejection, organ failure, genetic diseases, tumors, cancer, infertility | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHANGHAI BAO PHARMACEUTICALS CO., LTD.
- Other trademarks in Class 005
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 24, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 24, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 24, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 7, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 20, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 20, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 6, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 6, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 31, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 10, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 8, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 8, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 8, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 27, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 27, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 3, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 17, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 17, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 8, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 31, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 30, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 30, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |